---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-030814"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T17:21:57.877048+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biodesix FY2024 revenue $71.3M (+45% YoY); guides FY2025 $92-95M

## Summary
- FY2024 total revenue $71.3M, up 45% YoY; gross margin 78%, up 5 pts from FY2023.
- Lung Diagnostic testing revenue $64.7M (+43% YoY); Biopharma Services $6.6M (+70% YoY).
- Net loss $42.9M improved 18%; adjusted EBITDA loss $22.1M improved 32% vs FY2023.
- Cash $26.2M at Dec 31, 2024; post-quarter amended term loan to extend $10M Tranche C availability.
- FY2025 total revenue guidance $92-95M, representing 29-33% growth over FY2024.

## SEC filing metadata
- accession: 0000950170-25-030814
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000095017025030814/0000950170-25-030814-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000095017025030814/bdsx-20250303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-030814
- JSON: https://secwatch.observer/filing/0000950170-25-030814.json
- Plain text: https://secwatch.observer/filing/0000950170-25-030814.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.